D.E. Shaw & Co
DAWN

D.E. Shaw & Co’s Day One Biopharmaceuticals DAWN Stock Holding History

D.E. Shaw & Co’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$464K Sell
21,626
-293
-1% -$4.13K ﹤0.01% 3888
2025
Q4 		$204K Sell
21,919
-56,053
-72% -$468K ﹤0.01% 4321
2025
Q3 		$550K Sell
77,972
-3,331
-4% -$22.9K ﹤0.01% 3817
2025
Q2 		$528K Sell
81,303
-1,767
-2% -$12.2K ﹤0.01% 3617
2025
Q1 		$659K Sell
83,070
-63,315
-43% -$682K ﹤0.01% 3339
2024
Q4 		$1.85M Buy
146,385
+3,250
+2% +$45.2K ﹤0.01% 2785
2024
Q3 		$1.99M Sell
143,135
-81,205
-36% -$1.16M ﹤0.01% 2721
2024
Q2 		$3.09M Buy
224,340
+121
+0.1% +$1.77K ﹤0.01% 2242
2024
Q1 		$3.7M Buy
224,219
+28,730
+15% +$430K ﹤0.01% 2130
2023
Q4 		$2.85M Sell
195,489
-739
-0.4% -$8.96K ﹤0.01% 2383
2023
Q3 		$2.41M Sell
196,228
-17,188
-8% -$224K ﹤0.01% 2428
2023
Q2 		$2.55M Sell
213,416
-210,963
-50% -$2.76M ﹤0.01% 2434
2023
Q1 		$5.67M Sell
424,379
-176,943
-29% -$3.46M 0.01% 1827
2022
Q4 		$12.9M Buy
601,322
+34,174
+6% +$701K 0.01% 1217
2022
Q3 		$11.4M Buy
567,148
+428,830
+310% +$9.12M 0.01% 1246
2022
Q2 		$2.48M Buy
+138,318
New +$1.43M ﹤0.01% 2883
2022
Q1 		– Sell
-13,404
Closed -$226K – 5606
2021
Q4 		$226K Buy
+13,404
New +$275K ﹤0.01% 4818

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

D.E. Shaw & Co's DAWN Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Day One Biopharmaceuticals (DAWN) stake by 1.3% in Q1 2026, selling an estimated $4.13K and leaving 21,626 shares worth $464K. The position accounts for ﹤0.01% of the portfolio, ranked #3888.

D.E. Shaw & Co first reported a position in DAWN in Q4 2021 and has held it in 17 quarters since. The position peaked at $12.9M in Q4 2022. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • D.E. Shaw & Co held 21,626 shares of Day One Biopharmaceuticals worth $464K as of Q1 2026.
  • D.E. Shaw & Co sold 293 Day One Biopharmaceuticals shares in Q1 2026, an estimated $4.13K.
  • Day One Biopharmaceuticals made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #3888 holding.
  • D.E. Shaw & Co first reported a position in Day One Biopharmaceuticals in Q4 2021 and has held it in 17 quarters since.
  • D.E. Shaw & Co's Day One Biopharmaceuticals position peaked at $12.9M in Q4 2022.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.